Aravive Investor Presentation Deck

P1b ccRCC: Clinical Activity of Batiraxcept + Cabozantinib All P1b Patients (N=26) P1b 15 mg/kg (n=16) Efficacy Evaluable Best Response Confirmed Partial Response Confirmed Stable Disease Progressive Disease 2 9-month Progression-Free Survival 7-month Duration of Response 11 (42%) 11 (42%) 4 (15%) 65% 68% 8 (50%) 6 (38%) 2 (12%) 61% 67% P1b 20 mg/kg (n=10) 3 (30%) 5 (50%) 2 (20%) 79% 67% 1 Confirmed objective response rate for (60mg) cabozantinib from METEOR and CANTATA studies was 17% and 28%; Median PFS for (60mg) was 7.4 and 9.3 months; 9-month PFS 36% and 50% 2 No patient had PD at first scan: One patient had PR at first scan and then progressed; the other 2 patients were SD at first scan and then progressed Data cutoff August 8, 2022 24

View entire presentation